Kang Hyun-Seung, Han Moon Hee, Lee Tae Hong, Shin Yong Sam, Roh Hong Gee, Kwon O-Ki, Kwon Bae Ju, Kim Sun Yong, Kim Sung Hyun, Byun Hong Sik
Department of Neurosurgery, Konkuk University Hospital, Seoul, Korea.
Neurosurgery. 2007 Jul;61(1):51-8; discussion 58-9. doi: 10.1227/01.neu.0000279723.67779.f0.
HydroCoil (MicroVention, Aliso Viejo, CA), a hydrogel-platinum coil hybrid device, is one of various efforts to overcome delayed recanalization of coiled intracranial aneurysms. The purpose of this study was to investigate the outcome of intracranial aneurysms treated with HydroCoils.
This multicenter prospective study included 80 aneurysms in 76 patients treated with HydroCoils. There were 32 (40%) ruptured and 48 (60%) unruptured aneurysms; 22 (28%) were large aneurysms (maximal diameter, > or = 10 mm) and 58 (72%) were small. Aneurysm volumes were 100 mm3 or more in 48 (60%) and less than 100 mm3 in 32 (40%); in 13 aneurysms (16%), volumes were 600 mm3 or more. Efficacy and safety were evaluated on the basis of degree of initial occlusion, procedure-related complications, and the follow-up result.
Initial aneurysmal occlusion was complete in 60 (75%) aneurysms and near-complete in 14 (17.5%). Procedure-related complications included aseptic meningitis-related problems, including delayed hydrocephalus in 13 patients (28% among cases of unruptured aneurysms) and thromboembolism in two patients. Radiological follow-up data obtained 6 months or more after coil embolization were available in 54 aneurysms (68%) and revealed stable occlusion in 48 (89%) aneurysms, minor recanalization in one (2%), and major recanalization in five (9%). All of the recanalized aneurysms were 600 mm3 or more in volume, and aneurysm volume was a single important variable related to delayed recanalization on multiple logistic regression analysis (P = 0.016).
HydroCoil embolization seems to be a feasible treatment option in intracranial aneurysms in terms of initial aneurysmal occlusion rate and durability at the time of the follow-up evaluation; however, caution is required regarding aseptic meningitis and delayed hydrocephalus. Calculated aneurysmal volume of 600 mm3 seems to be critical in determining the anatomic outcome in aneurysms embolized with HydroCoils.
HydroCoil(MicroVention公司,美国加利福尼亚州阿利索维耶霍)是一种水凝胶-铂线圈混合装置,是为克服颅内动脉瘤弹簧圈栓塞术后延迟再通所做的多种努力之一。本研究旨在探讨使用HydroCoil治疗颅内动脉瘤的效果。
这项多中心前瞻性研究纳入了76例接受HydroCoil治疗的患者的80个动脉瘤。其中32个(40%)为破裂动脉瘤,48个(60%)为未破裂动脉瘤;22个(28%)为大型动脉瘤(最大直径≥10 mm),58个(72%)为小型动脉瘤。48个(60%)动脉瘤的体积为100 mm³或更大,32个(40%)动脉瘤的体积小于100 mm³;13个(16%)动脉瘤的体积为600 mm³或更大。根据初始闭塞程度、与手术相关的并发症及随访结果评估疗效和安全性。
60个(75%)动脉瘤实现了初始完全闭塞,14个(17.5%)动脉瘤实现了近乎完全闭塞。与手术相关的并发症包括无菌性脑膜炎相关问题,其中13例患者(在未破裂动脉瘤病例中占28%)出现迟发性脑积水,2例患者出现血栓栓塞。54个(68%)动脉瘤在弹簧圈栓塞术后6个月或更长时间获得了影像学随访数据,其中48个(89%)动脉瘤显示闭塞稳定,1个(2%)动脉瘤出现轻微再通,5个(9%)动脉瘤出现严重再通。所有再通的动脉瘤体积均为600 mm³或更大,在多因素logistic回归分析中,动脉瘤体积是与延迟再通相关的唯一重要变量(P = 0.016)。
就初始动脉瘤闭塞率和随访评估时的耐久性而言,HydroCoil栓塞术似乎是颅内动脉瘤的一种可行治疗选择;然而,对于无菌性脑膜炎和迟发性脑积水需要谨慎。计算得出的600 mm³动脉瘤体积似乎是决定HydroCoil栓塞动脉瘤解剖学转归的关键因素。